GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (OCSE:ORPHA) » Definitions » Operating Margin %

Orphazyme AS (OCSE:ORPHA) Operating Margin % : 0.00% (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Orphazyme AS Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Orphazyme AS's Operating Income for the six months ended in Jun. 2022 was kr-27.30 Mil. Orphazyme AS's Revenue for the six months ended in Jun. 2022 was kr0.00 Mil. Therefore, Orphazyme AS's Operating Margin % for the quarter that ended in Jun. 2022 was 0.00%.

The historical rank and industry rank for Orphazyme AS's Operating Margin % or its related term are showing as below:


OCSE:ORPHA's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -168.78
* Ranked among companies with meaningful Operating Margin % only.

Orphazyme AS's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Orphazyme AS's Operating Income for the six months ended in Jun. 2022 was kr-27.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2022 was kr-603.26 Mil.


Orphazyme AS Operating Margin % Historical Data

The historical data trend for Orphazyme AS's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Operating Margin % Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial - - - - -1,749.79

Orphazyme AS Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -1,591.35 -

Competitive Comparison of Orphazyme AS's Operating Margin %

For the Biotechnology subindustry, Orphazyme AS's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orphazyme AS's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Operating Margin % falls into.



Orphazyme AS Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Orphazyme AS's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-633.303 / 36.193
=-1,749.79 %

Orphazyme AS's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=-27.296 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orphazyme AS  (OCSE:ORPHA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Orphazyme AS Operating Margin % Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (OCSE:ORPHA) Business Description

Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (OCSE:ORPHA) Headlines

No Headlines